Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CytomX Therapeutics Q4 2023 GAAP EPS $0.01 Beats $(0.03) Estimate, Sales $26.607M Beat $21.043M Estimate

Author: Benzinga Newsdesk | March 11, 2024 04:06pm
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.03) by 133.33 percent. The company reported quarterly sales of $26.607 million which beat the analyst consensus estimate of $21.043 million by 26.44 percent. This is a 2.71K percent increase over sales of $946.000 thousand the same period last year.

Posted In: CTMX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist